Free parking at each visit
Psychosocial counseling
All visit procedures administered at no
cost
Transportation help if needed
About S-CitAD
The Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)
clinical research study is being conducted to determine if a study drug given as a pill can safely and
effectively reduce the symptoms of agitation and aggression in people with Alzheimer’s disease.
The
study will last approximately 3 months and will include 5 clinic study visits and at least 6 telephone
contact visits.
Participants will be randomized to receive either the study drug (escitalopram)
or a placebo (inactive substance) for the first 12 weeks.
HOME | ABOUT | CLINICS | FOR CLINICIANS
Escitalopram is a widely used generic drug approved for other indications by the FDA. It will be
administered orally in pill form. As with any medication, the study drug may cause side effects. There is
also no guarantee the study drug will be effective.
The study doctor will explain all potential
risks and benefits during your first visit, before you decide whether you want to participate in the
study.
There are strict laws governing the conduct of clinical studies. A process called informed consent ensures
you know all the facts regarding study participation prior to enrolling in the study. If you decide to
participate, you or your loved one will sign an informed consent document.
This document is not a
contract, and you may withdraw from the study at any time.
All participants will be monitored
throughout the study, and a team will be on hand to answer all questions related to the study.
The study drug and study-related procedures will be provided at no cost. Cost of travel related to the study
may be reimbursed.
The study is funded by the people of America through a grant from the US National
Institutes on Aging. The study has not received any funding from a pharmaceutical company.
If you (or someone you know) have dementia and struggle with agitation, irritability, or similar behaviors, you might be eligible to participate.